All Small Molecules articles
-
NewsBlood-thinning drug shows promise against osteoarthritis inflammation
Researchers have identified dabigatran, an approved anticoagulant, as a candidate for treating osteoarthritis after screening FDA-approved drugs for compounds capable of simultaneously suppressing two key inflammatory mediators.
-
NewsEnzyme structure mapped as new drug target for rare brain disorder
Scientists at the Icahn School of Medicine at Mount Sinai have resolved the complete structure of the AASS enzyme, revealing potential new strategies for treating the rare inherited metabolic disorder glutaric aciduria type 1.
-
NewsDALTAC prostate cancer strategy traps cancer proteins to overcome resistance
Researchers at the University of Michigan have developed a bifunctional small molecule approach that traps two prostate cancer-driving proteins in an inactive state.
-
NewsSodium-triggered gel reduces toxicity of bacterial cancer therapy
A sodium-responsive gel designed to encapsulate tumour-targeting Salmonella has demonstrated substantially reduced treatment toxicity without compromising anti-tumour activity in preclinical mouse models, potentially reviving interest in bacterial cancer therapies.
-
NewsRCF awards $1m to advance tau-targeting drug discovery
The Rainwater Charitable Foundation has awarded more than $1m through its Sprint to Lead programme to support three one-year projects targeting tau protein in primary tauopathies, including PSP, CBD and FTD.
-
NewsPsychedelics and cancer: exploring neurological pathways in tumour biology
A new peer-reviewed review explores whether psychedelic compounds could influence cancer biology through neurological and immune mechanisms, whilst identifying psychological wellbeing as the most credible near-term clinical opportunity.
-
Company profileLight-powered reaction converts sulfonamides into drug discovery building blocks
A light-driven chemical reaction developed at Florida State University can strip sulfur atoms from sulfonamides to produce anilines, offering a new route to repurpose previously intractable compounds for drug discovery.
-
NewsFramework proposed to advance plant-derived anti-inflammatory drug discovery
A review led by researchers at the Naval Medical University proposes a structured framework for evaluating plant-derived anti-inflammatory compounds, warning that pathway inhibition alone is insufficient evidence of direct molecular target engagement.
-
NewsPSD-95 inhibition identified as therapeutic target for MEF2C haploinsufficiency
Researchers at the University of Illinois Urbana-Champaign have identified PSD-95, a synaptic scaffolding protein, as a potential therapeutic target for neurological disorders associated with loss of the autism-linked gene MEF2C.
-
NewsTriptolide plant compound could improve response to epigenetic cancer drugs
Researchers at Johns Hopkins have identified a natural plant compound capable of blocking an enzyme that degrades DNA methyltransferase inhibitors, offering a potential strategy to overcome resistance to epigenetic cancer therapies.
-
ArticleStrong binding isn’t enough – why cellular target engagement matters
Promising compounds don’t always engage their targets in living cells. At ELRIG Drug Discovery 2026, Dr Joshua Sopp of Promega discusses why earlier cellular testing matters and how BRETSA could help researchers investigate new drug targets.
-
NewsANO6 protein identified as dual therapeutic target in pancreatic cancer
Researchers at Fox Chase Cancer Center have identified anoctamin 6 (ANO6) as a potential therapeutic target in pancreatic cancer, finding that blocking the protein disrupts both nutrient transfer to tumour cells and immune evasion in preclinical models.
-
Newsp53 activation boosts T-cell potency against solid tumours
UCLA researchers have shown that transiently activating the tumour suppressor protein p53 using an investigational MDM2 inhibitor can reduce exhaustion in engineered T cells and significantly improve their ability to kill melanoma cells in vitro.
-
NewsHidden bacterial compounds reveal potential cancer drug leads
Researchers have discovered a new family of bacterial natural products that bind the cancer-associated enzyme AKR1C3, revealing potential starting points for drug discovery.
-
NewsNew antifungal compound targets resistant fungi without kidney toxicity
Researchers have designed an antifungal compound that targets a molecular feature unique to fungi, showing activity against drug-resistant pathogens while avoiding kidney injury in preclinical studies.
-
NewsMLY2 and MLY8 compounds show promise as ulcerative colitis treatment candidates
Two experimental compounds derived from a phase II metabolite have demonstrated improved anti-inflammatory activity in preclinical models of ulcerative colitis.
-
NewsBCAT1 enzyme identified as fibrosis target after heart attack
Researchers at Nagoya University have identified BCAT1, an enzyme involved in proline supply for collagen synthesis, as a potential target for reducing cardiac fibrosis following myocardial infarction.
-
NewsKRAS inhibition and CTLA-4 blockade could overcome gastric cancer immunotherapy resistance
Researchers have identified oncogenic KRAS as a key driver of immunosuppression in gastric adenocarcinoma.
-
NewsCMA restoration may clear senescent cells in ageing tissues
Researchers at Albert Einstein College of Medicine have identified a cellular recycling pathway whose age-related decline allows senescent ‘zombie’ cells to evade immune clearance.
-
NewsInsilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Insilico Medicine has nominated ISM1354, an AI-designed small-molecule GIPR antagonist, as a preclinical candidate for obesity and related metabolic disorders.


